CNBC Top NewsQwen · 实盘不做把握 3/10不做原因:已被定价
北京时间·🕒 发布 08-26 23:51:05(美东 11:51)·⟳ 抓取 00:04:24 +13m19s·⚡ 决策 08-27 00:08:53 +4m29s·61.9 天前
FDA批准Revolution Medicines的first-in-class RAS抑制剂daraxonrasib(Rasonque)用于经治转移性胰腺癌
FDA批准是已知PDUFA日期的程序性落地，股价在批准前20日已涨+16.91%至52周高附近（$212.6 vs 52周高$220.34），市值$457亿已充分反映商业化预期。批准日股价无正向惊喜（开盘低于前收、日内大幅震荡收平），典型'buy the rumor, sell the news'格局，无剩余入场edge。
📄 原文CNBC Top News↗ 原文
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines' targeted drug for adults with metasta…
不做 Revolution Medicines（RVMD.US）
FDA批准为已知PDUFA日期的程序性落地，股价在批准前20日已涨+16.91%至52周高附近（$212.6，距高$220.34仅-4%），市值$457亿。批准日股价无正向惊喜（开盘低于前收、日内振幅$198.94-$216.5后收平），典型sell-the-news。无剩余预期差和入场edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
FDA批准daraxonrasib是first-in-class RAS抑制剂治疗胰腺癌的里程碑事件，但该批准在NDA受理（7月23日）后已被市场充分预期。RVMD在批准前20日涨+16.91%至$212.6（距52周高$220.34仅-4%），市值达$457亿。批准日股价开盘低于前收、日内振幅达$198.94-$216.5后收平，无正向surprise。按'预期差锚定'原则，这是程序性落地的明牌，无剩余交易edge。
🔎 新鲜度:最早出现 2026-08-26 · 扩散 high · price-in 风险 high ↗
消息传播链
- FDA正式批准消息于美东11:51由CNBC报道，此时RVMD股价已在$211附近（前收$211.38），无跳涨反应市场反应:股价当日开盘$209.32低于前收，盘中高见$216.5低见$198.94，收平于$211.51，无正向惊喜
主要风险
- 批准日股价无正向反应且日内大幅震荡（低见$198.94），显示获利盘抛压；定价和商业化细节未公布，若定价低于预期可能进一步承压
反向证据
- 做多前查反向 · 来源 stock_quote · 日期 2026-08-26 · 影响 invalidates
批准日股价开盘低于前收（$209.32 vs $211.38），盘中低见$198.94（-5.9%），收平于$211.51；20日已涨+16.91%，距52周高仅-4%，无正向惊喜
检索:RVMD股价走势与批准日价格反应
先例如何影响了这次决策
对本次决策的影响:先例缺失不改变结论：价格行为、市值水平和预期差分析已独立支持AVOID
方向:无法通过外部先例验证（web_search不可用），但股价行为本身已清晰表明充分定价
涨幅量级:无可用先例
形态:当日价格行为（开盘低于前收、大幅震荡收平）符合典型'见光死/ sell the news'模式
工具调用 · 历史记录,结果未知(7 种)
- fetch_decision_experience · 结果未知
- search_processed_events · 结果未知
- stock_quote · 结果未知
- web_search · 结果未知
- kb_search · 结果未知
- search_case_library · 结果未知
- direct_instrument_candidates · 结果未知
原文全文
展开原文 · 790 字
The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines' targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or cannot receive combination chemotherapy.
The drug, branded as Rasonque and also known as daraxonrasib, is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.
The approval was based on a study of 500 adults with previously treated metastatic pancreatic adenocarcinoma, the most common type of pancreatic cancer. The drug improved the rate of overall survival to 13.2 months, compared with 6.7 months on standard chemotherapy.
Revolution Medicines did not immediately respond to a Reuters request for comment on pricing and availability.
The drug, branded as Rasonque and also known as daraxonrasib, is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.
The approval was based on a study of 500 adults with previously treated metastatic pancreatic adenocarcinoma, the most common type of pancreatic cancer. The drug improved the rate of overall survival to 13.2 months, compared with 6.7 months on standard chemotherapy.
Revolution Medicines did not immediately respond to a Reuters request for comment on pricing and availability.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。